Cargando…
Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma?
BACKGROUND: Coagulation and fibrinolysis are distinct processes that are highly correlated. Cells control coagulation and fibrinolysis by expression of tissue factor and urokinase-type plasminogen activator receptor on their surface. Tumor cells express these proteins, adjust their microenvironment...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580209/ https://www.ncbi.nlm.nih.gov/pubmed/36258189 http://dx.doi.org/10.1186/s12885-022-10106-4 |
_version_ | 1784812341760622592 |
---|---|
author | Asanuma, Kunihiro Nakamura, Tomoki Okamoto, Takayuki Hagi, Tomohito Kita, Kouji Nakamura, Koichi Matsuyama, Yumi Yoshida, Keisuke Asanuma, Yumiko Sudo, Akihiro |
author_facet | Asanuma, Kunihiro Nakamura, Tomoki Okamoto, Takayuki Hagi, Tomohito Kita, Kouji Nakamura, Koichi Matsuyama, Yumi Yoshida, Keisuke Asanuma, Yumiko Sudo, Akihiro |
author_sort | Asanuma, Kunihiro |
collection | PubMed |
description | BACKGROUND: Coagulation and fibrinolysis are distinct processes that are highly correlated. Cells control coagulation and fibrinolysis by expression of tissue factor and urokinase-type plasminogen activator receptor on their surface. Tumor cells express these proteins, adjust their microenvironment and induce tumor exacerbation. We hypothesized that the expression of plasma markers for coagulation and fibrinolysis in patients with soft tissue sarcomas (STSs) was dependent on the level of tumor malignancy. To elucidate which markers are predictive of recurrence, metastasis and prognosis, coagulation or fibrinolysis, we analyzed the correlation between plasma levels of thrombin-antithrombin III complex (TAT), soluble fibrin (SF), plasmin-α2 plasmin inhibitor complex (PIC), D-dimer (DD) and clinical parameters in patients with STSs. METHODS: TAT, SF, PIC or DD were measured in pre-treatment blood samples from 64 patients with primary STSs and analyzed with clinicopathological parameters, and 5-year recurrence free survival (RFS), 5-year metastasis free survival (MFS) and 5-year overall survival (OS) were evaluated. RESULTS: The metastasis group had significantly higher DD (p = 0.0394), PIC (p = 0.00532) and SF (p = 0.00249) concentrations than the group without metastasis. The group that died of disease showed significantly higher DD (p = 0.00105), PIC (p = 0.000542), SF (p = 0.000126) and TAT (p = 0.0373) than surviving patients. By dividing the patients into low and high groups, the group with high DD, PIC, SF and TAT showed significantly lower 5-year MFS and 5-year OS than the corresponding low group. Furthermore, in multivariate COX proportional hazard analysis of continuous variables for 5-year MFS, only PIC was found to be a significant factor (HR: 2.14). CONCLUSION: Fibrinolysis was better than coagulation at reflecting the disease condition of patients with STS. Notably, PIC levels ≥ 1.1 can not only predict the risk of metastasis and poor prognosis, but also increasing PIC levels correspond to further increases in risks of metastasis and poor prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10106-4. |
format | Online Article Text |
id | pubmed-9580209 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-95802092022-10-20 Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? Asanuma, Kunihiro Nakamura, Tomoki Okamoto, Takayuki Hagi, Tomohito Kita, Kouji Nakamura, Koichi Matsuyama, Yumi Yoshida, Keisuke Asanuma, Yumiko Sudo, Akihiro BMC Cancer Research BACKGROUND: Coagulation and fibrinolysis are distinct processes that are highly correlated. Cells control coagulation and fibrinolysis by expression of tissue factor and urokinase-type plasminogen activator receptor on their surface. Tumor cells express these proteins, adjust their microenvironment and induce tumor exacerbation. We hypothesized that the expression of plasma markers for coagulation and fibrinolysis in patients with soft tissue sarcomas (STSs) was dependent on the level of tumor malignancy. To elucidate which markers are predictive of recurrence, metastasis and prognosis, coagulation or fibrinolysis, we analyzed the correlation between plasma levels of thrombin-antithrombin III complex (TAT), soluble fibrin (SF), plasmin-α2 plasmin inhibitor complex (PIC), D-dimer (DD) and clinical parameters in patients with STSs. METHODS: TAT, SF, PIC or DD were measured in pre-treatment blood samples from 64 patients with primary STSs and analyzed with clinicopathological parameters, and 5-year recurrence free survival (RFS), 5-year metastasis free survival (MFS) and 5-year overall survival (OS) were evaluated. RESULTS: The metastasis group had significantly higher DD (p = 0.0394), PIC (p = 0.00532) and SF (p = 0.00249) concentrations than the group without metastasis. The group that died of disease showed significantly higher DD (p = 0.00105), PIC (p = 0.000542), SF (p = 0.000126) and TAT (p = 0.0373) than surviving patients. By dividing the patients into low and high groups, the group with high DD, PIC, SF and TAT showed significantly lower 5-year MFS and 5-year OS than the corresponding low group. Furthermore, in multivariate COX proportional hazard analysis of continuous variables for 5-year MFS, only PIC was found to be a significant factor (HR: 2.14). CONCLUSION: Fibrinolysis was better than coagulation at reflecting the disease condition of patients with STS. Notably, PIC levels ≥ 1.1 can not only predict the risk of metastasis and poor prognosis, but also increasing PIC levels correspond to further increases in risks of metastasis and poor prognosis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10106-4. BioMed Central 2022-10-18 /pmc/articles/PMC9580209/ /pubmed/36258189 http://dx.doi.org/10.1186/s12885-022-10106-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Asanuma, Kunihiro Nakamura, Tomoki Okamoto, Takayuki Hagi, Tomohito Kita, Kouji Nakamura, Koichi Matsuyama, Yumi Yoshida, Keisuke Asanuma, Yumiko Sudo, Akihiro Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title | Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title_full | Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title_fullStr | Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title_full_unstemmed | Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title_short | Do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
title_sort | do coagulation or fibrinolysis reflect the disease condition in patients with soft tissue sarcoma? |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580209/ https://www.ncbi.nlm.nih.gov/pubmed/36258189 http://dx.doi.org/10.1186/s12885-022-10106-4 |
work_keys_str_mv | AT asanumakunihiro docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT nakamuratomoki docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT okamototakayuki docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT hagitomohito docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT kitakouji docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT nakamurakoichi docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT matsuyamayumi docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT yoshidakeisuke docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT asanumayumiko docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma AT sudoakihiro docoagulationorfibrinolysisreflectthediseaseconditioninpatientswithsofttissuesarcoma |